Biocept Target Selector Kits

Biocept has announced the availability of the first research-use-only (RUO) assay in a planned menu of kits for labs to run its Target Selector circulating tumor DNA assays in house.  The first assay being released is for high-sensitivity detection of EGFR mutations, which are among the most frequently evaluated biomarkers for lung cancer. Additional RUO test kits for other oncogene mutations are planned for launch in the future.

All will use Biocept's proprietary "switch blocker" technology, which the firm says produce industry-leading sensitivity for the detection of variants of interest. The EGFR kit and other assays can be used on a variety of analytical platforms including qPCR, Sanger sequencing, microarrays, mass-spectrometry, and next generation sequencing.